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The colliding epidemics of COVID-19, Ebola, and measles in 
the Democratic Republic of the Congo
The Democratic Republic of the Congo is facing 
major public health challenges due to a confluence 
of major outbreaks of Ebola virus disease, measles, 
and COVID-19.1–4 The tenth Ebola outbreak in 
eastern DR Congo began on Aug 1, 2018, and as of 
May 28, 2020, there have been 3406 Ebola virus disease 
cases with 2243 deaths. The Ebola virus disease outbreak 
was well controlled in northeast DR Congo following 
a multisectoral response, but four new confirmed 
Ebola cases were detected in northwest DR Congo on 
June 1, 2020, and an outbreak response is underway.4 
Additionally, the DR Congo has been burdened with 
recurrent measles outbreaks: 13 3802 cases in 2011, 
88 381 cases in 2013, and 311 471 cases in 2019.2 The 
first confirmed case of COVID-19 in DR Congo was 
diagnosed on March 10, 2020, and the government 
declared a state of emergency on March 24, 2020. A 
national multisectoral response committee instituted 
lockdown in the capital, Kinshasa, the epicentre of the 
epidemic in DR Congo, in which daily confirmed cases 
now average 100. As of June 16, 2020, 4777 COVID-19 
cases with 106 deaths have been reported from the DR 
Congo.5 
Although the COVID-19 pandemic presents unique 
challenges that threaten the health, economy, and social 
fabric of DR Congo, several lessons learned from dealing 
with the devastating Ebola virus disease outbreaks have 
been invaluable and are guiding the ongoing COVID-19 
public health response.6 These responses include 
involvement of community leaders and institutions 
with communication to the public in local languages 
to explain the disease and its prevention strategies and 
disseminating messages in terms that are culturally 
understandable. Ebola virus disease control infrastructure, 
protocols, and staff have been repurposed and applied to 
the COVID-19 response. Multidisciplinary teams of nurses, 
doctors, medical students, and community health-care 
workers are implementing COVID-19 sensitisation, 
screening, and testing activities endorsed by the Ministry 
of Health and community and religious leaders7.
All COVID-19 testing by RT-PCR is done at the 
National Institute of Biomedical Research in Kinshasa. 
Efforts to decentralise testing to provinces and 
improve turnaround are underway using point-of-care 
testing with the GeneXpert platform, but this remains 
challenging because of cost and supply constraints 
for severe acute respiratory syndrome coronavirus 2 
testing cartridges. Several hospitals were identified as 
reference centres for the treatment of COVID-19, and 
intensive care units have been resourced with additional 
ventilators and oxygen supplies as part of the national 
plan. A clinical protocol has been developed by the Case 
Management Commission with support from technical 
partners. Bilateral and multilateral partnerships 
provided donations of medical equipment to hospitals, 
and clinical staff are being trained on COVID-19 case 
management. Patients with moderate and severe 
COVID-19 are hospitalised for supportive care, oxygen 
therapy, and anticoagulation as per WHO guidelines.8
The strong national commitment in DR Congo to the 
COVID-19 and Ebola virus disease epidemics provides 
hope that alignment of public health responses will 
prevent the high morbidity and mortality seen in South 
Africa. The DR Congo government understands the 
importance of strengthening its health systems through 
establishing effective partnerships with international 
stakeholders who leverage their unique areas of 
expertise to achieve tangible results. However, as with 
other African countries, major challenges for COVID-19 
control remain. Mitigation measures such as travel 
bans and lockdowns in DR Congo are having negative 
socioeconomic effects on the population. Indeed, most 
citizens are unemployed and live below the poverty line 
in shanty towns or rural settings in overcrowded housing, 
which makes COVID-19 preventive measures, such as 
hand washing and social distancing, difficult. Also, the 
high prevalence of comorbidities, including chronic 
conditions such hypertension, diabetes, HIV and AIDS, 
and tuberculosis, add to the COVID-19 mortality risk.9 
Although attention has been focused on COVID-19 and 
Ebola virus disease, there have also been 369 520 measles 
cases with 6779 deaths in the past year, which illustrates 
that vaccination efforts have been suboptimal because 
of disruptions to immunisation campaigns and suggests 
that there are potential threats of resurgence of other 
vaccine-preventable infectious diseases.
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DR Congo’s early COVID-19 mitigation interventions 
have allowed the multisectoral response committee 
to gain time and prepare for the anticipated COVID-19 
peak, but its response is being implemented in a fragile 
health system that faces challenges, including the 
coexisting Ebola virus disease and measles outbreaks. 
The World Bank provided US$300 million to support 
the 2018–2020 Ebola virus disease response strategy, 
and it should ensure that additional assistance includes 
support for primary health care and regular supply of 
essential medicines, vaccines, and technical assistance.10 
Although urgent measures are required to slow the 
spread of COVID-19 and tackle the renewed threat 
of Ebola virus disease, every effort must be made by 
stakeholders to ensure that prevention programmes 
for measles or other infectious diseases, including 
transporting vaccinations for children, are not 
compromised.
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